Oncogenic driver mutations, i.e., KRAS, have been shown to reprogram multiple metabolic pathways in pancreatic ductal adenocarcinoma (PDAC) to support growth and proliferation [34]. The gene discussed is KRAS; the disease is pancreatic ductal adenocarcinoma.